We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
A material-event filing was submitted. Check the category (guidance / executives / M&A, etc.).
Consensus vs. actual, and revenue trend
Consensus PT $252.9 · 29 analysts
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Stored first · Google News · Yahoo Finance (English)
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue? Yahoo Finance
AbbVie (ABBV) Expands Venclyxto Label for Chronic Lymphocytic Le - GuruFocus
AbbVie (ABBV) Expands Venclyxto Label for Chronic Lymphocytic Le GuruFocus
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? - Yahoo Finance
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? Yahoo Finance
Assessing AbbVie (ABBV) Valuation After FDA Approval Of Decnupaz For Ultra Rare Blood Cancer - simplywall.st
Assessing AbbVie (ABBV) Valuation After FDA Approval Of Decnupaz For Ultra Rare Blood Cancer simplywall.st
AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations - StreetInsider
AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations StreetInsider
Joseph Susa: Response to the FDA Approval of Abbvie’s New Antibody Conjugated Drug - Oncodaily
Joseph Susa: Response to the FDA Approval of Abbvie’s New Antibody Conjugated Drug Oncodaily
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $3.77 | — | — | $16.76B | — | Scheduled |
| FY2026 Q1 | 2026. 05. 08. | Time TBD | — | $0.72 | — | — | $13.34B | Reported |
| FY2025 Q3 | 2025. 11. 04. | Time TBD | — | $2.41 | — | — | $41.23B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.53 | — | — | $26.77B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 16. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 15. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 05. 04. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 02. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 05. 01. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 01. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 178,418 | $38.8B | 0.03% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 114,712 | $26.21B | 0.04% | — | New position |